Bristol-Myers Squibb's (BMY) Milvexian Can Reset Sentiment Positively - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $45.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
